Close Menu

NEW YORK (360Dx) — Akers Biosciences said today that it has signed a sales and marketing agreement with independent sales representative (ISR) firm Appleton Medical Services for its rapid test for heparin-induced thrombocytopenia (HIT).

Akers Bio's PIFA Heparin/PF4 Rapid Assay is designed to quickly determine if a patient may be developing thrombocytopenia while being treated with the blood thinner heparin at or near the point of care.

To read the full story....

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.

Don't have a 360Dx or GenomeWeb account?
Register for Free.